CFO will alter on 1 February, 2021 Helsinki Inventory Trade:BONEH

BBS-Bioactive Bone Substitutes Plc, Enterprise Announcement on 1 February 2021 at 3:35 pm (UTC +2:00)

MSc. (Tech) Liisa Hukka from Talenom Plc. has been appointed chief economic officer (CFO) of BBS-Bioactive Bone Substitutes PlC (”BBS”, ”the Company”). Hukka will get up her posture on 1 February, 2021, when the Company’s latest CFO Hannu Säynäjäkangas retires. Hukka is effective on BBS’ Management Group and stories to the CEO.  

Hukka has extensive encounter in industrial money management in both of those worldwide detailed corporations and domestic development businesses. She is specialised in economical management in changeover and advancement phases of companies. For the previous 5 a long time, Hukka has labored as a fiscal administration specialist at Talenom. Prior to that, she labored as CFO at Nestor Cable and in many economic administration and business support positions at the Dutch Draka Holding BV Group. Hukka holds M.Sc. in Creation Management. She also retains MSc from Cranfield College in the Uk.  

With the adjust of CFO, BBS has switched to working with Talenom’s accounting organization and monetary management products and services.

The company’s Administration Group is made up of Ilkka Kangasniemi CEO, Liisa Hukka CFO, Soile Hakala QD, Hanna Tölli COO and Mikko Viitanen Director of QC.

A lot more data:
Ilkka Kangasniemi, CEO
[email protected]
+358 40 7080307

Nasdaq Helsinki Oy
Nasdaq Stockholm AB
Main Media

BBS – Bioactive Bone Substitutes Plc

BBS-Bioactive Bone Substitutes Plc is a Finnish orthobiologic biotech company. We have produced a new item for healing of complicated bone fractures and for resolving the complications in bone therapeutic. Our mission is to supply new technology medicinal products and solutions for the orthopedic medical procedures. The research and enhancement in the subject of medication demands perseverance and braveness to establish new items.  We have about 20 many years of skills in this. Our operations are characterised by best experience, innovativeness and focused and fully commited staff. The initially merchandise, ARTEBONE® paste, is ready and the software approach for the CE-marking enabling commercialization is in progress.

Much more information and facts:

BBS-Bioactive Bone Substitutes Plc shares are listed on the Nasdaq Initially North Development Industry Finland and Nasdaq Initial North Advancement Sector Sweden. The company’s Certified Adviser is Stockholm Certified Advisers AB, p. +46 70 5516 729, [email protected]